Talking Tumors: Filling Data Gaps in Multiple Myeloma
November 14th 2019We sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.
Read More
Ruxolitinib Hits Primary Endpoint in Phase III Acute GVHD Trial
October 17th 2019Ruxolitinib met the primary endpoint of the phase III REACH2 trial, improving the overall response rate at day 28 versus best available therapy in patients with in patients with steroid-refractory acute graft-versus-host disease.
Read More
Talking Tumors: Adaptive Approaches in Triple-Negative and HR-Positive Breast Cancers
October 16th 2019In keeping up with the expanding breast cancer treatment armamentarium, we sat down with Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, who shed light on emerging treatment strategies for patients with metastatic triple-negative breast cancer and discussed the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.
Read More
BCMA Antibody-Drug Conjugate Belantamab Mafodotin Succeeds in Phase II Myeloma Trial
August 23rd 2019Belantamab mafodotin met the primary endpoint of demonstrating a clinically meaningful overall response rate in patients with relapsed/refractory multiple myeloma, according to topline results from the phase II DREAMM-2 trial.
Read More
FDA Grants Enzalutamide Priority Review for Metastatic Hormone-Sensitive Prostate Cancer
August 21st 2019The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.
Read More
Higher Anthracycline Doses Linked to Breast Malignancy Risk in Childhood Cancer Survivors
July 5th 2019Higher doses of anthracyclines are associated with increased risk of breast cancer in women who survived childhood cancer, regardless of whether they have mutations that predispose them to cancer.
Read More
Published Data Back Regorafenib Dose Escalation in Colorectal Cancer
July 3rd 2019A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer.
Read More
Talazoparib Approaches EU Approval for BRCA-Mutated, HER2-Negative Breast Cancer
April 30th 2019The European Medicines Agency's Committee for Medicinal Products for Human Use has backed approval of talazoparib (Talzenna) for adult patients with HER2-negative locally advanced or metastatic breast cancer harboring germline BRCA1/2 mutations.
Read More
Encorafenib/Binimetinib-based Triplet Added to NCCN Guidelines for BRAF+ CRC
March 18th 2019The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.
Read More
Frontline Olaparib Maintenance Improves PFS in BRCA+ Pancreatic Cancer
February 26th 2019Frontline maintenance therapy with olaparib significantly reduced the risk of disease progression or death versus placebo in patients with germline BRCA-mutated metastatic adenocarcinoma of the pancreas, according to findings from the phase III POLO trial.
Read More
Tivozanib Improves PFS in Highly Refractory RCC
November 6th 2018The VEGF inhibitor tivozanib reduced the risk of disease progression or death by 26% compared with sorafenib in patients with highly refractory advanced or metastatic RCC, according to topline findings from the phase III TIVO-3 trial.
Read More